Skip to main content
SpringerLink
Log in

CSF somatostatin increase in patients with early parkinsonian syndrome

  • Full Papers
  • Published:
Journal of Neural Transmission - Parkinson's Disease and Dementia Section

Summary

Somatostatin-like immunoreactivity levels (SLI) in cerebrospinal fluid (CSF) were determined in twenty-three patients with untreated parkinsonian syndrome (15 with Idiopathic Parkinson's disease (IPD) and 8 with other forms of parkinsonism) at the moment of clinical diagnosis (mean duration of disease 1.1±0.2 years), and in 26 subjects without neurological symptoms. None of the IPD patients had a diagnosis of dementia at the moment of inclusion in the study. CSF-SLI content was found to be significantly higher in patients with parkinsonian syndrome (107.9±9.8 pg/ml) than in control subjects (73.5±8.4 pg/ml). The increase was also significant when controls were compared with IPD patients. In addition, a positive correlation between SLI and homovanillic acid was found in CSF of all patients. A test of learning memory was used to evaluate the mental state of patients and a significant increase in CSF-somatostatin levels was observed in patients with Idiopathic Parkinson's disease and severe affectation of memory. These results indicate that in the early steps of untreated parkinsonian syndrome, somatostatin concentration in cerebrospinal fluid may increase, probably due to the neurodegenerative depletion of somatostatin from striatal or cortical neurons.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Achilli G Perego C, Ponzio F (1985) Application of the dual-cell coulometric detector: a method for assaying monoamines and their metabolites. Anal Biochem 148: 1–9

    Article  PubMed  Google Scholar 

  • Agid Y, Cervera P, Hirsch E, Javoy-Agid F, Lehericy S, Raisman R, Ruberg M (1989) Biochemistry of Parkinson's disease 28 years later: a critical review. Mov Disord 4:S1: 126–144

    Article  Google Scholar 

  • Arimura A, Sato H, Coy DH, Schally AV (1975) Radioimmunoassay of GH-release inhibiting hormone. Proc Soc Exp Biol Med 148: 784

    PubMed  Google Scholar 

  • Beal MF, Martin JB (1984). The effect of somatostatin on striatal catecholamines. Neurosci Lett 44: 271–276

    Article  PubMed  Google Scholar 

  • Beal MF, Mazurek MF, Black P, Martin JB (1985) Human cerebrospinal fluid somatostatin in neurologic disease. J Neurol Sci 71: 91–104

    Article  PubMed  Google Scholar 

  • Beal MF, Growdon JH, Mazurek MF, Martin JB (1986a) CSF somatostatin-like immunoreactivity in dementia. Neurology 36: 294–297

    PubMed  Google Scholar 

  • Beal MF, Mazurek MF, Martin JB (1986b) Somatostatin immunoreactivity is reduced in Parkinson's disease dementia with Alzheimer's changes. Brain Res 397: 386–388

    Article  PubMed  Google Scholar 

  • Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4: 561–571

    PubMed  Google Scholar 

  • Bisette G, Myers B (1992) Minireview: somatostatin in Alzheimer's disease and depression. Life Sci 51: 1389–1410

    Article  PubMed  Google Scholar 

  • Calne DB, Snow BJ, Lee C (1992) Criteria for diagnosing Parkinson's disease. Ann Neurol 32: S125-S127

    Article  PubMed  Google Scholar 

  • Chesselet MF, Reisine TD (1983) Somatostatin regulates dopamine release in rat striatal slices and cat caudate nuclei. J Neurosci 3: 232–236

    PubMed  Google Scholar 

  • Chia L-G Cheng F-C, Kuo J-S (1993) Monoamines and their metabolites in plasma and lumbar cerebrospinal fluid of Chinese patients with Parkinson's disease. J Neurol Sci 116: 125–134

    Article  PubMed  Google Scholar 

  • Crespi F (1993) Functional in vivo interaction between growth hormone and dopamine systems are correlated to changes in striatal somatostatin levels as detected by voltammetry. Exp Brain Res 94: 363–370

    Article  PubMed  Google Scholar 

  • Dupont E, Christensen SE, Hansen AP, et al (1982) Low cerebral fluid somatostatin in Parkinson disease: an irreversible abnormality. Neurology 32: 312–314

    PubMed  Google Scholar 

  • Epelbaum J, Ruberg M, Moyse E., Jovoy-Agid F, Dubois B, Agid Y (1983) Somatostatin and dementia in Parkinson's disease. Brain Res 278: 376–379

    Article  PubMed  Google Scholar 

  • Espino A, Ambrosio S, Bartrons R, Bendahan G, Calopa M (1994) Cerebrospinal monoamine metabolites and amino acid content in patients with parkinsonian syndrome and rats lesioned with MPP+. J Neural Transm [P-D Sect] 7: 167–176

    Article  Google Scholar 

  • Evarts EV, Teräräinen H, Calne DB (1981) Reaction time in Parkinson's disease. Brain 104: 167–186

    PubMed  Google Scholar 

  • García Sevilla JA, Athee L, Magnusson T, Carlsson A (1978) Opiate receptor mediated changes in monoamine synthesis in rat brain. Pharm Pharmacol 30: 613–621

    Google Scholar 

  • Hartikainen P, Soininen H, Reinikainen KJ, Sirviö J, Soikkeli R, Riekkinen PJ (1991) Neurotransmitter markers in the cerebrospinal fluid of normal subjects. Effects of aging and other confounding factors. J Neural Transm [GenSect] 84: 103–117

    Article  Google Scholar 

  • Hoehn MM, Yahr MD (1967) Parkinsonism: onset progression and mortality. Neurology 17: 427–442

    PubMed  Google Scholar 

  • Huber SJ, Shutteleworth EC, Christy JA, Chakeres DW, Curtin A, Paulson GW (1989) Magnetic resonance imaging in dementia of Parkinson's disease. J Neurol Neurosurg Psychiatry 52: 1221–1227

    PubMed  Google Scholar 

  • Hugues AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181–184

    PubMed  Google Scholar 

  • Jolkkonen J, Soininen H, Halonen T, Ylinen A, Laulumaa V, Laakso M, Riekkinen P (1986) Somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with Parkinson's disease and its relation to dementia. J Neurol Neurosurg Psychiatry 49: 1374–1377

    PubMed  Google Scholar 

  • Jost S, Reuner C, Mohadjer M, Mundinger F, Cramer H (1990) Ventricular fluid neuropeptides in Parkinson's disease. Neuropeptides 15: 219–225

    Article  PubMed  Google Scholar 

  • Lang AE, Fann S (1989) Assesment of Parkinson's disease. In: Munsat TL (ed) Quantification of neurologic deficit. Butterworths, Boston, pp 285–309

    Google Scholar 

  • LeWitt PA, Galloway MP, Matson W, Milbury P, McDermott M, Srivastava DK, Oakes D, Parkinson Study Group (1992) Markers of dopamine metabolism in Parkinson's disease. Neurology 42: 2111–2117

    PubMed  Google Scholar 

  • Masson H, Popescu I, Strubel D, Cramer H, Kuntzmann F (1990) Somatostatin-like immunoreactivity in the cerebrospinal fluid of aged patients with Parkinson's disease. The effect of dopatherapy. J Am Geriatr Soc 38: 19–24

    PubMed  Google Scholar 

  • Poewe W, Benke T, Karamat E, Schelosky L, Wagner M (1990) CSF somatostatin-like immunoreactivity in dementia of Parkinson's disease. J Neurol Neurosurg Psychiatry 53: 1105–1106

    Google Scholar 

  • Rey A (1964) L'examen clinique en psychologie. Presses Universitaires de France, Paris

    Google Scholar 

  • Schneider E, Fischer P, Jacobi P, Becker H, Harker H (1979) The significance of cerebral atrophy for the symptomatology of Parkinson's disease. J Neurol Sci 42: 187–197

    Article  PubMed  Google Scholar 

  • Strittmatter MM, Cramer H (1992) Parkinson's disease and dementia: clinical and neurochemical correlations. Neuroreport 3 413–416

    PubMed  Google Scholar 

  • Tohgi H, Abe T, Takahashi S, Nozaki Y, Ueno M, Kikuchi T (1993) Monoamine metabolism in the cerebrospinal fluid in Parkinson's disease: relationship to clinical symptoms and subsequent therapeutic outcomes. J Neural Transm [P-D Sect] 5: 17–26

    Article  Google Scholar 

  • Volicer L, Beal MF, Direnfeld LK, Marquis JK, Albert ML (1986) CSF cyclic nucleotides and somatostatin in Parkinson's disease. Neurology 36: 89–92

    PubMed  Google Scholar 

Download references

Author information

Author notes

  1. A. Espino

    Present address: Unitat de Bioquímica, Facultat d'Odontologia, C/Feixa Llarga s/n, 08907, L'Hospitalet, Barcelona, Spain

Authors and Affiliations

  1. Department of Neurology, Hospital Prínceps d'Espanya, Spain

    A. Espino, M. Calopa & J. Peres

  2. Hormone Unit, Hospital Prínceps d'Espanya, Spain

    J. Ortolà & M. A. Navarro

  3. Unitat de Bioquímica, Facultat d'Odontologia, C/Feixa Llarga s/n, 08907, L'Hospitalet, Barcelona, Spain

    S. Ambrosio

Authors
  1. A. Espino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Calopa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Ambrosio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Ortolà
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Peres
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. A. Navarro
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Espino, A., Calopa, M., Ambrosio, S. et al. CSF somatostatin increase in patients with early parkinsonian syndrome. J Neural Transm Gen Sect 9, 189–196 (1995). https://doi.org/10.1007/BF02259660

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02259660

Keywords

Search

Navigation